GW Pharmaceuticals

Our vision is to be the global leaders in prescription cannabinoid medicines, through the rapid cost-effective development of pharmaceutical products which address clear unmet needs.
GW is developing a portfolio of cannabinoid medicines, including Sativex for the treatment of MS spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy.

Type
Public
HQ
Histon, GB
Founded
1998
Size (employees)
496 (est)+28%
GW Pharmaceuticals was founded in 1998 and is headquartered in Histon, GB

GW Pharmaceuticals Office Locations

GW Pharmaceuticals has offices in Histon, London, Carlsbad
Histon, GB (HQ)
Vision Park
Carlsbad, US
210 5800 Armada Dr
London, GB
1 Cavendish Pl

GW Pharmaceuticals Metrics

GW Pharmaceuticals Financial Metrics

Revenue (2016)

£10.3 m

Revenue growth (2015-16), %

(64%)

Gross profit

£7.6 m

Gross profit margin (2016), %

74%

Net income (2016)

(£63.7 m)

Market capitalization (21-Mar-2017)

$3.1 b

Closing share price (21-Mar-2017)

$122.5

Cash (30-Sep-2016)

£374.4 m
GW Pharmaceuticals's current market capitalization is $3.1 b.
GW Pharmaceuticals's revenue was reported to be £10.3 m in FY, 2016 which is a 63.9% decrease from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

£27.3 m£30 m£28.5 m£10.3 m

Revenue growth, %

10%(5%)(64%)

Cost of goods sold

£1.3 m£2.1 m£2.6 m£2.7 m

Gross profit

£26 m£28 m£25.9 m£7.6 m

Gross profit Margin, %

95%93%91%74%

Operating expense total

£36.5 m£47.6 m£83.2 m£94.2 m

Pre tax profit

(£19.6 m)(£57.1 m)(£86.2 m)

Net Income

(£14.7 m)(£44.6 m)(£63.7 m)
FY, 2014FY, 2015FY, 2016

Cash

£164.5 m£234.9 m£374.4 m

Accounts Receivable

£612 k£373 k£778 k

Current Assets

£176.4 m£255.1 m£404.5 m

PP&E

£11.9 m£29.2 m£42.8 m

Goodwill

£5.2 m£5.5 m£5.8 m

Total Assets

£193.5 m£289.7 m£453.2 m

Accounts Payable

£2.3 m£3.8 m£3.4 m

Current Liabilities

£17.3 m£27.8 m£35 m

Retained Earnings

(£14.7 m)(£44.6 m)(£63.7 m)

Total Equity

£158.6 m£245.3 m£398.5 m

Financial Leverage

1.2 x1.2 x1.1 x
FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

(£12.6 m)(£46.5 m)(£84.6 m)

Cash From Financing Activities

£144.3 m£128.4 m£206.8 m

Income Taxes Paid

£4.9 m£12.5 m£22.5 m

GW Pharmaceuticals Market Value History

GW Pharmaceuticals News

GW Pharmaceuticals Company Life

You may also be interested in